"Nolpaza" is a hypoacid agent related to antiulcer drugs, to the group that inhibits the proton pump. The drug is used for the prevention and treatment of pathologies of the digestive tract. The drug Nolpaza has analogues, such as Panum, Zipantola, Kontrolok, Peptazol, Sanpraz, Pantaz. All of them have in their composition the active substance "pantoprazole", which dose-dependently and for a long time acts to suppress the secretion of hydrochloric acid.
The composition and form of release of the drug "Nolpaza"
The instruction reports that 1 tablet of the gastro-resistant drug Nolpaza 20 contains 20 mg of pantaprazole. In the tablet "Nolpaza 40" - 40 mg of the active substance. There are also excipients in the preparation, including sorbitol.
Pharmaceutical action of the drug "Nolpaza"
The instruction refers the drug to antiulcer drugs - proton pump inhibitors (H + K + ATPase). The medicine has the ability to permanently suppress the secretion of hydrochloric acid. The drug is active against Helicobacter pylori and is able to enhance the anti-helicobacter effect of other drugs.
After taking the Nolpaza tablet, the therapeutic effect is manifested rather soon and continues throughout the day. With an intravenous injection of 80 mg of the drug, the antisecretory effect reaches a peak within an hour and persists for a day, which contributes to the rapid reduction of symptoms and the healing of ulcers in the duodenum. When taken orally, complete absorption occurs rapidly. To a small extent, the drug has the ability to penetrate the BBB, along with the secret it appears in breast milk. The metabolism of the drug occurs in the liver. In the form of metabolites excreted mainly in the urine, in small quantities can be found in the stool. It does not have a cumulative ability.
Indications for the drug "Nolpaza"
The instruction provides for the use of the drug for:
- gastroesophageal reflux pathology of a mild degree;
- for the prevention and treatment of patients with reflux esophagitis at any stage;
- for the treatment of people with gastric or intestinal peptic ulcer, with Zollinger-Ellison syndrome and other conditions accompanied by hypersecretion;
- with the goal of preventing ulcers in patients who have long received non-steroidal anti-inflammatory drugs.
The drug "Nolpaza" can be prescribed in combination therapy with antimicrobial drugs to destroy Helicobacter pylori.
Contraindications to the drug "Nolpaza"
The instruction does not recommend the use of the drug in case of hypersensitivity, hepatitis and cirrhosis, accompanied by severe liver failure .
Restrictions on the use of the drug "Nolpaza"
- with impaired liver function,
- in childhood,
- during pregnancy, lactation.
Side effects
In the organs of the gastrointestinal tract are manifested:
- diarrhea;
- dry mouth
- increased appetite,
- nausea
- burping
- vomiting
- flatulence,
- abdominal pain
- constipation
- increased activity of transaminases,
gastrointestinal carcinoma.
In the nervous system and sensory organs:
- a headache;
- asthenia, dizziness, drowsiness, insomnia;
- nervousness, depression, tremor, paresthesia;
- photophobia, visual impairment, tinnitus.
In the genitourinary system:
- hematuria,
- swelling,
- impotence.
On the skin:
- alopecia,
- acne
- exfoliative dermatitis,
- allergic reactions in the form of a rash, urticaria, itching, angioedema.
Others in the form of:
- hyperglycemia, myalgia;
- fever, eosinophilia, hyperlipoproteinemia, hypercholesterolemia.
Interaction with other drugs
With the simultaneous use of the drug "Nolpaza" with other medicines, the digestibility of ketoconazole and some other drugs with a pH-dependent absorption decreases.
Application methods
Nolpaza tablets are taken orally, 40 mg - 1 dose per day, in the morning. The maximum dose of the drug is twice as much.
In the treatment of ulcerative lesions caused by Helicobacter pylori, treatment regimens are used in conjunction with clarithromycin and metronidazole.
Overdose
No description of symptoms. In case of an overdose, it is recommended to carry out supportive and symptomatic therapy. Dialysis in this case is considered ineffective.
special instructions
Before treatment, it is necessary to exclude the presence of malignant diseases of the esophagus and stomach. It is not recommended to prescribe non-ulcer etiology to patients with dyspepsia. Elderly patients and impaired renal function are not recommended to give a dose exceeding 40 mg / day. If there is severe liver failure, the dosage regimen must be adjusted by monitoring the level of liver enzymes.